signal transduction inhibitor

sig·nal trans·duc·tion in·hib·i·tor

(STI) (sig'năl trans-dŭk'shŭn in-hib'i-tŏr)
Category or classification of anticancer drugs that inhibit the action of enzymes essential to the growth and survival of cancer cells while causing relatively little or no damage to noncancer cells.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Mentioned in ?
References in periodicals archive ?
Imatinib is a signal transduction inhibitor; it inhibits the oncogenic tyrosine kinase BCR-ABL, c-KIT, and PDGF-R.
APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug in Phase I/IIa clinical prostate trial that was initiated in August 2011.
Additionally, the first of the three drugs to enter the clinic will be APC-100, an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
Adamis' APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
Hormonal therapies, signal transduction inhibitors, gene expression modulators, and immunotherapies are among the targeted therapies approved for cancer treatment
Measurement of MAP kinase by flow cytometry using phosphor-specific antibodies to MEK and ERK: potential for pharmacodynamics monitoring of signal transduction inhibitors. Cytometry.
The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter.
Novel combination treatment strategies are evolving that employ signal transduction inhibitors alongside existing hormonal therapies.
We have to overcome the concept of "magic bullets." We have to consider everything that our clinical colleagues have done, during the course of the years, using cytotoxic therapies, and we have to take advantage of that wealth of knowledge, and ask how can we integrate cytotoxic agents with differentiating agents and signal transduction inhibitors and apply it to a particular patient's tumor?
In this collection of 11 articles, contributors describe their work in PTKs in such areas as using PTKs as targets for cancer and other indications, targeting Src homology 2 domains in drug discovery, using P12-kinase inhibition as a target for therapeutic intervention, using an activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia and JAK kinases in leukemia, lymphomas and multiple myeloma, applying platelet-derived growth factor, using a targeted therapy for myelogenous leukemia, testing signal transduction inhibitors in animal models of cancer, and using phosphoproteomics in drug discovery and development.
The company's broad 20 product pipeline leverages five different therapeutic approaches, including LHRH antagonists and signal transduction inhibitors. The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide.
Signal transduction inhibitors, a new class of cancer drugs targeting solid tumors without the toxic side effects of chemotherapy, are causing treatment-resistant folliculitis in up to 75% of patients.

Full browser ?